NEIMETH INTERNATIONAL PHARMACEUTICAL PLC (NEIMETH)
Nigerian Stock Exchange · Nigeria · prices in NGN · close of 21 Oct 2026
Key indicators
| Last close | NGN 7.600 |
|---|---|
| 52-week range | 4.950 – 16.150 |
| Return, 1 month / 3 months | +4.1% / −17.8% |
| Return, 1 year / 3 years | +26.7% / +390.3% |
| Trend | Below its 200-day average |
| RSI (14) | 49 |
| Volatility (1 year) | 85.6% |
| Worst drawdown (1 year) | -55.8% |
| Average daily value traded | 21.71M NGN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Neimeth International Pharmaceuticals is a Nigerian pharmaceutical company based in Lagos. It develops, manufactures and markets medicines and healthcare products, including antimalarial and antibiotic treatments, as well as other prescription and consumer health items. Its customers include hospitals, pharmacies, clinics and distributors across Nigeria, and it also provides contract manufacturing services for other healthcare businesses. The company traces its origins to a former Pfizer manufacturing operation in the country.
NEIMETH INTERNATIONAL PHARMACEUTICAL PLC trades under the code NEIMETH on the Nigerian Stock Exchange in Nigeria, with its price quoted in Nigerian naira (NGN). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
NEIMETH INTERNATIONAL PHARMACEUTICAL PLC (NEIMETH) trades on the Nigerian Stock Exchange in Nigeria. It last closed at NGN 7.600 on 21 October 2026.
Its price-based Market X-Ray is 30 out of 100 (a weak price profile), ranking 128 of 157 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 26.7% and over the last three months it fell 17.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nigerian Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 22 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -18.9% | ||
| From 52-week high | -48.3% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.8% | ||
| 6-month return | -24.0% | ||
| 12-month return, skipping the last month | 21.7% | ||
| Stability (higher is calmer) | 17 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 85.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -55.8% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 21.71M NGN | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −3.8% |
|---|---|
| 1 month | +4.1% |
| 3 months | −17.8% |
| 6 months | −24.0% |
| 1 year | +26.7% |
| 3 years | +390.3% |
| 5 years | +331.8% |
Signals
| 50-day / 200-day average | 7.644 / 9.368 |
|---|---|
| Golden / death cross (60 days) | Death, 47 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.491 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Mar 2022 | NGN 0.0700 |
| 23 Feb 2021 | NGN 0.0650 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nigerian Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.